Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06366750 · ClinicalTrials.gov registry record · Phase 2

A Study of Barzolvolimab in Patients With Prurigo Nodularis

A Phase 2 study of Prurigo Nodularis, sponsored by Celldex Therapeutics.

Active
Registry status
Phase 2
Development phase
140
Enrollment target
20
Study locations

NCT06366750 is a Phase 2 study of Prurigo Nodularis that is active but no longer recruiting, run by Celldex Therapeutics. The registered enrollment target is 140 participants, below the 219-participant average among 14 other Prurigo Nodularis trials with a reported enrollment target (36% lower). The trial reports 20 study locations across 5 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06366750, a Phase 2 study of Prurigo Nodularis, is active but no longer recruiting, sponsored by Celldex Therapeutics.

ACTIVE NOT RECRUITING
Registry status
Phase 2
Development phase
140 participants
Enrollment target
20
Study locations

Study Summary

The purpose of this study is to assess the efficacy and safety of barzolvolimab in adults with prurigo nodularis.

Conditions Studied

Prurigo Nodularis

Interventions

  • OTHER Matching Placebo
  • BIOLOGICAL barzolvolimab

Study Locations (20)

California

  • Center for Dermatology Clinical Research, Inc - Fremont
  • Profound Research LLC - Oceanside
  • Empire Clinical Research - Pomona
  • University of California San Francisco - San Francisco
  • University of California, San Francisco - San Francisco
  • Dermatology Institute & Skin Care Center - Santa Monica
  • Focus Clinical Research - West Hills

Florida

  • Encore Medical Research Boynton Beach - Boynton Beach
  • Biobrilliance Medical Research Center - Hialeah
  • Encore Medical Research - Hollywood
  • Life Arc Research Centers Corp - Miami
  • University of Miami - Miami
  • Advanced Clinical Research Institute - Tampa
  • Encore Medical Research of Weston - Weston

Alabama

  • Total Dermatology - Birmingham
  • Cahaba Dermatology Skin Health Center - Birmingham

Arizona

  • Investigate MD, LLC - Scottsdale
  • Scottsdale Clinical Trials - Scottsdale

Georgia

  • Emory University - Atlanta
  • Centricity Research - Columbus

Trial Details

FieldValue
Enrollment Target 140 participants
Start Date 2024-04-12
Est. Completion 2027-03
Phase Phase 2

Sponsor

Celldex Therapeutics

42 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06366750

The ClinicalTrials.gov registry entry for NCT06366750 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 140 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 219-participant average among 14 other Prurigo Nodularis trials with a reported enrollment target (36% lower). The listed sponsor is Celldex Therapeutics, which has 42 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Prurigo Nodularis appearing as the primary indexed condition, and to 2 interventions - of which Matching Placebo is the first listed.

NCT06366750 reports 20 study locations spanning 5 distinct geographic areas - top geographies include California, Florida, Alabama.

Frequently Asked Questions

What is clinical trial NCT06366750 about?

NCT06366750 is a clinical study titled "A Study of Barzolvolimab in Patients With Prurigo Nodularis". The purpose of this study is to assess the efficacy and safety of barzolvolimab in adults with prurigo nodularis.

What is the current status of trial NCT06366750?

This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 140 participants. The study started on 2024-04-12. Estimated completion is 2027-03.

What conditions does trial NCT06366750 study?

This clinical trial studies the following conditions: Prurigo Nodularis.

What interventions are being tested in trial NCT06366750?

The interventions under investigation include: Matching Placebo (OTHER), barzolvolimab (BIOLOGICAL).

Who is sponsoring clinical trial NCT06366750?

This trial is sponsored by Celldex Therapeutics, which has 42 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06366750 being conducted?

This trial has 20 study locations across Alabama, Arizona, California, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Prurigo Nodularis

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Prurigo Nodularis

All registered trials for this condition

Alabama

All trials with a study site in Alabama

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.